Sequential Y90 liver radioembolization and portal vein embolization: an additional strategy to downstage liver tumors and to enhance liver hypertrophy before major hepatectomies
- 28 August 2023
- journal article
- research article
- Published by Springer Nature in Langenbeck's Archives of Surgery
- Vol. 408 (1) , 1-7
Abstract
Background Yttrium (Y)90 liver radioembolization (TARE) induces both tumor downsizing and contralateral liver hypertrophy. In this study, we report the preliminary results of a sequential strategy combining Y90 radioembolization and portal vein embolization (PVE) before major right liver resections. Methods We retrospectively reviewed clinical, radiological, and biological data of 5 consecutive patients undergoing Y90 TARE-PVE before major right liver resections. Comparison was made with patients undergoing PVE alone or liver venous deprivation (LVD) during the same period. Results Between January 2019 and September 2022, five patients underwent sequential TARE-PVE. Type of resection included the following: right hepatectomy (n = 1), right hepatectomy + 1 (n = 2), and right hepatectomy + 1 + 4 (n = 2) with no postoperative mortality. Volumetric data showed a mean hypertrophy ratio of 30.4% after TARE and an additional 37.4% after sequential PVE. Patients undergoing sequential TARE-PVE had higher hypertrophy ratio (p = 0.02; p = 0.004), hypertrophy degree (p = 0.02; p < 0.0001), shorter time to normalize bilirubin (p = 0.04), and prothrombin time (p = 0.003; p < 0.0001) compared with patients receiving LVD or PVE. Time from diagnosis to surgery was statistically significant longer in patients undergoing sequential TARE-PVE compared with LVD or PVE (293.4 ± 169.1 vs 54.18 ±18.26 vs 58.62±13.15; p = 0.0008; p = <0.0001). Conclusions This preliminary report suggests that sequential PVE and TARE can represent a safe and an alternative strategy to downstage liver tumors and to enhance liver hypertrophy before major hepatectomies. When compared with PVE and LVD, sequential TARE/PVE takes longer times but achieves some advantages which warrant further evaluation in a larger setting.Keywords
This publication has 20 references indexed in Scilit:
- Radioembolisation and portal vein embolization before resection of large hepatocellular carcinomaWorld Journal of Gastroenterology, 2015
- Left-Liver Hypertrophy After Therapeutic Right-Liver Radioembolization Is Substantial but Less Than After Portal Vein EmbolizationHepatology, 2013
- Response to radioembolization with yttrium-90 resin microspheres may allow surgical treatment with curative intent and prolonged survival in previously unresectable hepatocellular carcinomaEuropean Journal of Surgical Oncology, 2012
- Posthepatectomy liver failure: A definition and grading by the International Study Group of Liver Surgery (ISGLS)Surgery, 2011
- Bile leakage after hepatobiliary and pancreatic surgery: A definition and grading of severity by the International Study Group of Liver SurgerySurgery, 2011
- Safety of Hepatic Resection in Metastatic Disease to the Liver After Yttrium-90 TherapyJournal of Surgical Research, 2011
- Is Selective Internal Radioembolization Safe and Effective for Patients with Inoperable Hepatocellular Carcinoma and Venous Thrombosis?Journal of the American College of Surgeons, 2009
- Preoperative contralateral portal vein embolization before major hepatic resection is a safe and efficient procedure: A large single institution experienceSurgery, 2008
- Classification of Surgical ComplicationsAnnals of Surgery, 2004
- During liver regeneration following right portal embolization the growth rate of liver metastases is more rapid than that of the liver parenchymaBritish Journal of Surgery, 1999